RESUMO
AIM: The expression of CD95(Fas/APO-1) antigen was studied on bone marrow cells of 19 MDS patients, peripheral blood blast cells of 15 acute myeloid leukemia (AML) patients, blast cells and granulocytes of 68 patients with chronic myeloid leukemia (CML)--24 in chronic, 9 in accelerated phase and 35 in blastic crisis (BC)--by indirect surface immunofluorescence assay using flow cytometry (FACScan, Becton Dickinson, USA). RESULTS: CD95(Fas/APO-1) antigen was revealed on bone marrow cells of 8 out of 19 (36.8%) MDS patients; the percentage of antigen-positive cells was 38.1 +/- 19.2%; on 45.5 +/- 22.8% of cells in 6(45%) of 15 AML patients. Fas/APO-1 antigen was totally absent in CML chronic stage; its expression was found in 34% (12 of 35) of our patients with CML BC on peripheral blood blasts and in 56% (5 of 9) on peripheral blast cells of CML patients in acceleration phase. CONCLUSION: The data on overall survival of CD95-positive MDS patients suggest that the presence of Fas antigen is a favorable prognostic sign for patients with MDS. The patients from CD95-negative group represent a risk group both for survival and AML transformation. In CML BC group the survival does not depend upon Fas-antigen expression.
Assuntos
Células Sanguíneas/imunologia , Células da Medula Óssea/imunologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/imunologia , Leucemia Mieloide/imunologia , Síndromes Mielodisplásicas/imunologia , Receptor fas/análise , Doença Aguda , Anticorpos Monoclonais , Crise Blástica/imunologia , Crise Blástica/mortalidade , Humanos , Leucemia Mielogênica Crônica BCR-ABL Positiva/mortalidade , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Leucemia Mieloide/mortalidade , Leucemia Mieloide/patologia , Síndromes Mielodisplásicas/mortalidade , Síndromes Mielodisplásicas/patologia , PrognósticoAssuntos
Anticorpos Monoclonais/imunologia , Apoptose/imunologia , Receptor fas/análise , Animais , Anticorpos Monoclonais/biossíntese , Especificidade de Anticorpos , Células Apresentadoras de Antígenos/imunologia , Células Sanguíneas/imunologia , Linhagem Celular , Criança , Feminino , Técnica Indireta de Fluorescência para Anticorpo , Humanos , Masculino , Camundongos , Coloração e Rotulagem , Células Tumorais Cultivadas , Receptor fas/sangue , Receptor fas/imunologiaAssuntos
Linfoma não Hodgkin/diagnóstico , Adolescente , Criança , Pré-Escolar , Diagnóstico Diferencial , Humanos , Lactente , MasculinoRESUMO
The paper deals with the analysis of the phenotype of blastic cells obtained from patients suffering various subtypes (FAB-classification) of acute nonlymphoblastic leukemia. The study used monoclonal IKO-GM-1 antibodies complementary to an antigen common to myeloid and macrophagal cells. Also, previously described monoclonal IKO-11, IKO-1, IKO-02 and IKO-10 antibodies were employed. Application of the above antibodies appeared to provide information necessary for differentiating between myeloblastic and monoblastic leukemia. Complex immunologic and cytochemical investigations are required for identifying leukemia subtypes.